Kite’s Yescarta (axicabtagene ciloleucel) Receives EC’s Approval for the Treatment of Relapsed or Refractory Follicular Lymphoma
- The EC has approved Yescarta for the treatment of adult patients with r/r FL after ≥3 lines of systemic therapy incl. the combination of an anti-CD20 mAb & alkylating agent
- The approval was based on the P-II (ZUMA-5) international study in 122 patients aged ≥18yrs. which showed ORR (91%) and CR rate (77%) at 24mos. analysis, m-DoR (38.6mos.), responders still in response (56%) @24mos.
- The safety profile was consistent with the known safety profile for Yescarta in all evaluable patients within ZUMA-5, grades ≥3 CRS were reported in 6% of patients, and neurologic events in 16% of patients, 99% of any grade resolved by the time of data cut-off and 60% of neurologic events were resolved within 3wks.
Ref: Businesswire | Image: Kite
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at [email protected].